Matinas Biopharma Holdings Inc(MTNB) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 29 at 4:15 AM ET (Korea 9/29 17:15)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -18.01 | Insider Own | 21.07% | Shs Outstand | 1.0M | Perf Week | -3.01% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 0.8M | Perf Month | -15.67% |
| Enterprise Value | 0.00B | PEG | - | EPS next Q | - | Inst Own | 2.21% | Short Float | 3.8% | Perf Quarter | -74.6% |
| Income | -0.01B | P/S | - | EPS this Y | - | Inst Trans | -1.11% | Short Ratio | 0.08 | Perf Half Y | -69.92% |
| Sales | 0.00B | P/B | 0.6 | EPS next 5Y | - | ROA | -98.53% | Short Interest | 0.03M | Perf YTD | -71.22% |
| Book/sh | 4.21 | P/C | 3.06 | EPS past 3/5Y | 25.49% 19.44% | ROE | -154.28% | 52W High | -91.52% ($29.85) | Perf Year | -91.12% |
| Cash/sh | 0.83 | P/FCF | - | Sales past 3/5Y | - | ROIC | -404.93% | 52W Low | 12.06% ($2.26) | Perf 3Y | -97.41% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 68.91% | Gross Margin | - | Volatility(W/M) | 8.86% 8.99% | Perf 5Y | -99.76% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.32 | Perf 10Y | -99.8% |
| Dividend Ex-Date | - | Quick Ratio | 0.85 | EPS Q/Q | 79.92% | Profit Margin | - | RSI (14) | 39.79 | Recom | 2 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.85 | Sales Q/Q | - | SMA20 | -5.59% ($2.68) | Beta | 2.08 | Target Price | $450 |
| Payout | - | Debt/Eq | 0.01 | Earnings | - | SMA50 | -24.4% ($3.35) | Rel Volume | 0.32 | Prev Close | $2.4 |
| Employees | 4 | LT Debt/Eq | 0.01 | EPS/Sales Surpr. | 19.43% - | SMA200 | -68.24% ($7.97) | Avg Volume(3M) | 0.37M | Price | $2.53 |
| IPO | 2014/7/21 | Option/Short | No/Yes | Trades | 1090 | Volume | 118,121 | Change | 5.42% |
💊 This is a US clinical-stage biotech with a proprietary Lipid Nano-Crystal (LNC) drug delivery platform. Its lead candidate is an oral formulation of Amphotericin B (MAT2203) targeting invasive fungal infections, and it is a micro-cap name that has significantly reduced its workforce and is exploring strategic alternatives following the collapse of global partnership negotiations in 2024.
Over the past 1 year, on the lower side
92% below its 1-year high.
Traded less than usual That is 32% of its average volume.
MTNB has weak earning power
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -99.8%. The S&P 500 did +77% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 2.2%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
VXF Vanguard Extended Market Index ETF <0.01% It ranks #579 of 592 in the industry
Based on market cap of $2M.
SILO#578 SILO Pharma Inc $3M PER - MTNB#579 Matinas Biopharma Holdings Inc $2M PER - 
PPBT#580 Purple Biotech Ltd ADR $2M PER - 
VBIO#581 Valion Bio Inc $2M PER - 
ARTL#582 Artelo Biosciences Inc $2M PER - 
FAQ
What kind of company is MTNB?
MTNB belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of MTNB?
The market cap of MTNB is approximately $2M, ranking 5,821 within its sector.
What is the 52-week high and low for MTNB?
MTNB has recorded a 52-week high of $29.85 and a low of $2.26.
